VEEV

VEEV

Veeva Systems

Recurring SaaS

★ Quality 44/100
Overvalued

Price today

$275.09

This company value is already calculated

We know what it is worth from its audited numbers, and whether it trades above or below that today. Create your free account to see it.

See what it is worth

charlieapp.co

What this business is made of

44qualityReturnsMoatBalance sheetPricing powerReinvestment

The business

Pharma's operating system: leaving means revalidating with the FDA.

Veeva sells custom-built cloud software for pharma and biotech: clinical trial management, regulatory data, and commercial CRM. It charges recurring subscriptions, with $3.2B in revenue and 76% gross margins. The life sciences industry doesn't ask for discounts; it asks that it works.

It's embedded in pharma's regulated workflows — switching systems means revalidating processes with the FDA, something nobody does on a whim. It knows a single vertical client's business better than a generic Salesforce. Not a monopoly, but the cost of leaving is high and the data is sticky.

Revenue history

$1.9B
2022
$2.2B
2023
$2.4B
2024
$2.7B
2025
$3.2B
2026
CAGR 5 años: +14%

From $1.9B to $3.2B in 4 years. The business grows steadily.

Where each $100 of sales goes

Revenue $3.2B · FY2026

Cost of sales$782M · 25%
Operations$1.5B · 47%
Net profit$909M · 28%

Of every $100 in sales, $72 goes to costs and operations; $28 is left as net profit (28% margin).

Catalysts and risks

Full migration to Vault CRM after dropping Salesforce, deadline 2025 — retention of its installed base.

Expansion into adjacent sectors (cosmetics, chemicals, food) on the same Vault platform.

Growth in data products (Veeva Data Cloud) competing with IQVIA, higher margin and recurrence.

⚠️

FCF reported at $0.0B this cut: watch cash conversion closely, it's not trivial for a mature SaaS.

⚠️

Dependence on a single vertical — a cut in pharma R&D spending hits it head-on.

⚠️

The moat is not monopoly-grade; a deep-pocketed competitor can attack niches like CRM.

Charlie's note

Paying 23.49x for a business growing 15% with 76% gross margin and embedded in workflows the FDA forces you to revalidate is no gift, but no madness either. The data stickiness justifies waiting calmly.

Analysis · June 2026

Want to follow Veeva Systems?

We do not calculate a value here: Veeva Systems does not generate cash flows you can project, and putting a number on it would be making it up. What you can do is follow it and tell us the price you care about — we will email you when it gets there.

🔔 Email me

Free · no card

Charlie informs, it doesn't advise. No information should be taken as a recommendation to buy or sell.